Trial Profile
Study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase II study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Selegiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors FP Pharmaceutical Corp
- 16 Jun 2016 New trial record